Access
This article is part of Nature's premium content.
Published online 1 April 2008 | Nature | doi:10.1038/452510a
Drug markers questioned
A recent spate of worrying clinical-trial data has researchers questioning drugs approved on the basis of how they affect biomarkers rather than clinical endpoints. Heidi Ledford looks at surrogate markers.
To read this story in full you will need to login or make a payment (see right).
Comments
Reader comments are usually moderated after posting. If you find something offensive or inappropriate, you can speed this process by clicking 'Report this comment' (or, if that doesn't work for you, email redesign@nature.com). For more controversial topics, we reserve the right to moderate before comments are published.
